כמות מזומנים למניה Prothena Corporation (PRTA)

Prothena Corporation (PRTA) is an Irish biotech company whose revenues are based on one-time partner payments, which renders profits volatile. The cash per share history on GURU.Markets illustrates the business's level of protection, where the current value is 5.30. Drug development is accelerating through AI, although testing still requires physicians. The ecosystem relies on loyal patients and FDA approval.
פילוחי מדדים מקיפים ואנליטיקה עבור Prothena Corporation (PRTA)

For Prothena Corporation (PRTA), whose development depends on the clinical trial stages of drugs targeting neurodegeneration, liquidity is a key survival factor. Analyzing cash per share over the period allows for a comparison of actual cash reserves against the number of shares, determining the company's ability to fund R&D without cash flow gaps and assessing the fundamental resilience of capital against cost inflation.